lists patented inventions available for sale or licensing. Inventors can list their patented inventions (or patent pending) for sale. New inventions for sale are added on a daily basis !
Home    List your patent    My account     Help     Support us    


[Category : - HEALTH]
[Viewed 151 times]

Over the last decade, there has been an increased interest in crystal engineering (e.g. salts) research to enhance drug solubility and mechanical properties. About 40% of the drugs in the discovery pipeline are failing out due to poor solubility with massive inherent costs (over £20 billion a year) and lengthy time. Thus, there is a clear market need to develop methods to make drugs more soluble. We propose a multi-disciplinary study involving continuous manufacturing (CM) of pharmaceutical salts (SiSTME) to tackle this growing need. Batch processes are highly costs and time intensive with low plant productivity. Thus, a CM process eliminating intermediate steps will improve product quality assurance. SiSTME (a process to manufacture salts of poorly water soluble weak acidic drugs in presence of neutral components such as a base with/without any addition of solvents) is an easy to scale up, economically practical and solvent free (with an option to use liquid if required) process with fewer processing steps. Apart from saving time and costs, CM via SiSTME can dramatically reduce building, energy and carbon footprints. The optimization and consequent development of this study is very crucial to the economic impact as it relates the global pharmaceutical needs to its implementations. This project entirely fits within the regulatory priority remit by providing state-of-the-art experimental techniques tuned to the current problems of pharmaceutical salts manufacturing and scale up.
SiSTME aims to disclose, for the first time, the study of feasibility of CM of salts of various water insoluble drugs (e.g. ibuprofen, phenytoin, diclofenac, and indomethacin).

The proposed development of SiSTME will indeed accelerate industrial interest in this field, providing direct benefits to the European pharmaceutical sector and wider long-term benefits to public health through the feasibility of otherwise unusable drugs.
Pharmaceutical salts are crystals that contain two or more neutral components (both solid at ambient temperatures), present in stoichiometric amounts. To date, salts are an emerging interest in pharmaceutical drug development to improve the solubility, dissolution and thus bioavailability of various poorly water soluble drugs. Salts enable the modification of key physicochemical properties of pharmaceuticals (e.g. stability) that impact on processing, pharmacokinetics, efficacy, toxicity, stability and design of the final dosage forms. As a result there is growing interest in the development of salts of active pharmaceutical ingredients (APIs).

Up to date, the ‘solvent growth method’ and ‘mechanical method’ are two most common techniques that have been used to make pharmaceutical salts. But in reality none of the techniques except the solvent growth method is scalable and all of them are time consuming. Excessive use of solvent can be harmful and costly as well and small residues of solvent can be toxic which can again raise regulatory issues. Another disadvantage of using the solvent growth method is the dispersion of two molecules in same solvent, which is not always possible as it creates equilibrium solubility difficulties.

[ Home | List a patent | Manage your account | F.A.Q.|Terms of use | Contact us]

Copyright 2004-2017
Page created at 2024-07-15 1:44:13, Patent Auction Time.